Enanta Pharmaceuticals (ENTA) Receivables: 2012-2025
Historic Receivables for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $6.9 million.
- Enanta Pharmaceuticals' Receivables rose 3.55% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year decrease of 3.34%. This contributed to the annual value of $6.9 million for FY2025, which is 3.55% up from last year.
- According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Receivables is $6.9 million, which was down 17.41% from $8.3 million recorded in Q2 2025.
- In the past 5 years, Enanta Pharmaceuticals' Receivables registered a high of $27.6 million during Q4 2021, and its lowest value of $6.6 million during Q3 2024.
- Moreover, its 3-year median value for Receivables was $8.2 million (2023), whereas its average is $9.6 million.
- Its Receivables has fluctuated over the past 5 years, first climbed by 15.93% in 2021, then tumbled by 63.81% in 2023.
- Enanta Pharmaceuticals' Receivables (Quarterly) stood at $27.6 million in 2021, then dropped by 18.31% to $22.6 million in 2022, then plummeted by 63.81% to $8.2 million in 2023, then dropped by 5.57% to $7.7 million in 2024, then increased by 3.55% to $6.9 million in 2025.
- Its last three reported values are $6.9 million in Q3 2025, $8.3 million for Q2 2025, and $6.8 million during Q1 2025.